Last update 20 Mar 2025

Peceleganan

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Antimicrobial Peptides PL-5, 抗菌肽PL-5
Target
Action
inhibitors
Mechanism
PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC138H226N36O34
InChIKeyIUYWAZJIRQDBEJ-XECNVCPKSA-N
CAS Registry850761-47-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Infectious DiseasesNDA/BLA--
Wound InfectionPhase 3
China
23 Aug 2021
Bacterial InfectionsPhase 2
United States
11 May 2023
Diabetic foot infectionPhase 2
United States
-
Secondary infectionDiscovery
China
28 Jul 2020
Post-traumatic wound infectionDiscovery
China
24 Jul 2018
Burn infectionsDiscovery
China
07 Nov 2016
Diabetic FootDiscovery
China
07 Nov 2016
ImpetigoDiscovery
China
07 Nov 2016
UlcerDiscovery
China
07 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ADA2024
ManualManual
Not Applicable
47
PL-5 spray
(srxluocqdj) = qoxoizwvrf mtltffcdsv (vhbyayfxen )
Positive
21 Jun 2024
Placebo
(srxluocqdj) = czpktsqjvh mtltffcdsv (vhbyayfxen )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free